- Home
- BIP vs MRNA Comparison
BIP vs MRNA Comparison
Compare BIP & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIP
- MRNA
- Stock Information
- Founded
- BIP 2007
- MRNA 2010
- Country
- BIP Bermuda
- MRNA United States
- Employees
- BIP N/A
- MRNA N/A
- Industry
- BIP Marine Transportation
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BIP Consumer Discretionary
- MRNA Health Care
- Exchange
- BIP Nasdaq
- MRNA Nasdaq
- Market Cap
- BIP 15.2B
- MRNA 16.0B
- IPO Year
- BIP 2008
- MRNA 2018
- Fundamental
- Price
- BIP $32.98
- MRNA $35.53
- Analyst Decision
- BIP Strong Buy
- MRNA Hold
- Analyst Count
- BIP 5
- MRNA 20
- Target Price
- BIP $42.80
- MRNA $59.65
- AVG Volume (30 Days)
- BIP 428.4K
- MRNA 13.6M
- Earning Date
- BIP 01-30-2025
- MRNA 02-14-2025
- Dividend Yield
- BIP 5.01%
- MRNA N/A
- EPS Growth
- BIP N/A
- MRNA N/A
- EPS
- BIP 0.12
- MRNA N/A
- Revenue
- BIP $21,039,000,000.00
- MRNA $3,236,000,000.00
- Revenue This Year
- BIP N/A
- MRNA N/A
- Revenue Next Year
- BIP $6.85
- MRNA $22.19
- P/E Ratio
- BIP $270.64
- MRNA N/A
- Revenue Growth
- BIP 17.33
- MRNA N/A
- 52 Week Low
- BIP $24.84
- MRNA $29.25
- 52 Week High
- BIP $36.50
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- BIP 50.93
- MRNA 48.60
- Support Level
- BIP $32.42
- MRNA $32.78
- Resistance Level
- BIP $33.58
- MRNA $36.98
- Average True Range (ATR)
- BIP 0.81
- MRNA 2.50
- MACD
- BIP 0.02
- MRNA 0.30
- Stochastic Oscillator
- BIP 79.28
- MRNA 66.81
About BIP Brookfield Infrastructure Partners LP
Brookfield Infrastructure Partners LP is a Bermuda exempted limited partnership that owns and operates quality, long-life assets that generate stable cash flows, by virtue of barriers to entry or other characteristics that tend to appreciate in value over time. It focuses on acquiring infrastructure assets that have low maintenance capital costs and high barriers to entry. The company's segments consist of Utilities, Transport, Midstream, and Data. Geographically, it generates maximum revenue from Canada and also has a presence in Australia, Colombia, United Kingdom, Brazil, United States of America, Chile, Peru, and other countries.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.